Aditya Bardia
A5034972183- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- DNA Repair Mechanisms
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- COVID-19 and healthcare impacts
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
UCLA Jonsson Comprehensive Cancer Center
2019-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2018-2025
University of California, San Francisco
2023-2025
Institut Gustave Roussy
2025
University of California, Los Angeles
2024-2025
UCLA Health
2024-2025
Fudan University Shanghai Cancer Center
2024
Harbin Medical University
2019-2024
Epithelial-mesenchymal transition (EMT) of adherent epithelial cells to a migratory mesenchymal state has been implicated in tumor metastasis preclinical models. To investigate its role human cancer, we characterized EMT circulating (CTCs) from breast cancer patients. Rare primary simultaneously expressed and markers, but were highly enriched CTCs. Serial CTC monitoring 11 patients suggested an association CTCs with disease progression. In index patient, reversible shifts between these cell...
A multistage microfluidic chip is capable of sorting rare EpCAM + and − CTCs from cancer patients’ whole blood.
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which expressed in majority cancers, coupled to SN-38 (topoisomerase I inhibitor) through proprietary hydrolyzable linker.
Circulating tumor cells (CTCs) are present at low concentrations in the peripheral blood of patients with solid tumors. It has been proposed that isolation, ex vivo culture, and characterization CTCs may provide an opportunity to noninvasively monitor changing patterns drug susceptibility individual as their tumors acquire new mutations. In a proof-of-concept study, we established CTC cultures from six estrogen receptor-positive breast cancer. Three five lines tested were tumorigenic mice....
An earlier analysis of this phase 3 trial showed that the addition a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided greater benefit with regard progression-free survival than alone in premenopausal or perimenopausal patients advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report results protocol-specified interim key secondary end point overall survival.We randomly assigned receive either...
Standard chemotherapy is associated with low response rates and short progression-free survival among patients pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), SN-38, conjugated to antibody by cleavable linker. enables delivery of high concentrations SN-38 tumors.
Patients with pretreated estrogen receptor (ER)-positive/human epidermal growth factor 2 (HER2)-negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies.
Abstract Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer and transduced were resistant to fulvestrant ± or palbociclib. This resistance was abrogated by treatment FGFR tyrosine kinase (TKI) lucitanib. Addition TKI erdafitinib palbociclib/fulvestrant induced complete responses patient-derived-xenografts. Next generation sequencing circulating tumor...
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an conjugate, targets Trop-2 the selective delivery of SN-38, active metabolite irinotecan. Patients and Methods We evaluated sacituzumab govitecan single-arm, multicenter trial patients with relapsed/refractory metastatic TNBC who received 10 mg/kg starting dose on days 1 8 21-day repeated cycles. The primary end points were safety...
Metastasis: A matter of translation? Solid tumors shed a small number cancer cells into the bloodstream, some which are believed to contribute metastasis. The molecular features that confer these circulating tumor (CTCs) with metastatic potential poorly understood. Ebright et al. studied CTCs from breast patients and found increased expression levels certain ribosomal proteins regulators translation had greater capacity in mouse model (see Perspective by Ma Jeffrey). Consistent this finding,...
Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in phase I/II multicenter trial (NCT01631552) patients with advanced epithelial cancers. This report summarizes the safety data from overall population (OSP) data, including additional disease cohorts not published previously.Patients refractory metastatic cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1...